Mohty M, Peyriere H, Guinet C, Hillaire-Buys D, Blayac J P, Rossi J F
Hematology and Medical Oncology Department, Hôpital Lapeyronie, Montpellier, France.
Leuk Lymphoma. 2000 Apr;37(3-4):441-3. doi: 10.3109/10428190009089446.
We report here the case of a 68-year-old woman who presented severe renal failure following the first cycle of high dose methotrexate (HDMTX) for the treatment of a cerebral malignant lymphoma. Before HDMTX administration, serum creatinine value was normal and three days after HDMTX, it reached 457 micromol/L. Leucovorin rescue, hemodialysis and cholestyramine did not increase MTX clearance. Because of the persistence of renal failure, and the high risk of important hematological side-effects associated with high MTX plasma levels, the patient received carboxypeptidase G2 (CPDG2). This allowed MTX plasma levels to decrease by 80% in 15 minutes. No side effects were observed and renal function normalized rapidly. In some patients, when high-dose leucovorin associated with hemodialysis and cholestyramine are unable to restore normal MTX clearance, CPDG2 should be considered because it may represent a safe and efficient alternative for the management of MTX intoxication.
我们在此报告一例68岁女性患者,其在接受首个周期大剂量甲氨蝶呤(HDMTX)治疗脑恶性淋巴瘤后出现严重肾衰竭。在给予HDMTX之前,血清肌酐值正常,而在HDMTX治疗三天后,该值达到457微摩尔/升。亚叶酸钙解救、血液透析和考来烯胺均未增加甲氨蝶呤清除率。由于肾衰竭持续存在,且与高血浆甲氨蝶呤水平相关的严重血液学副作用风险较高,该患者接受了羧肽酶G2(CPDG2)治疗。这使得甲氨蝶呤血浆水平在15分钟内下降了80%。未观察到副作用,且肾功能迅速恢复正常。在一些患者中,当大剂量亚叶酸钙联合血液透析和考来烯胺无法恢复正常甲氨蝶呤清除率时,应考虑使用CPDG2,因为它可能是治疗甲氨蝶呤中毒的一种安全有效的替代方法。